| Previous Close | 36.73 |
| Open | 36.79 |
| Bid | 36.57 x 4000 |
| Ask | 36.57 x 3200 |
| Day's Range | 36.46 - 36.81 |
| 52 Week Range | 26.45 - 43.08 |
| Volume | 30,144,940 |
| Avg. Volume | 46,476,456 |
| Market Cap | 202.882B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 23.73 |
| EPS (TTM) | 1.54 |
| Earnings Date | Feb. 02, 2021 |
| Forward Dividend & Yield | 1.56 (4.25%) |
| Ex-Dividend Date | Jan. 28, 2021 |
| 1y Target Est | 41.79 |
- Reuters
COVID SCIENCE-S. African virus variant may resist antibody drugs; Pfizer/BioNTech vaccine seems to work vs UK variant
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. The variant of the new coronavirus identified in South Africa can resist, or "escape," antibodies that neutralize earlier versions of the virus, scientists have found. It "exhibits complete escape" from three classes of monoclonal antibodies manufactured for treating COVID-19 patients, and it shows "substantial or complete" resistance to neutralizing antibodies in blood donated by COVID-19 survivors, the scientists reported on Tuesday on bioRxiv ahead of peer review.
- Reuters
Ivory Coast says delivery of its first doses of Pfizer vaccine delayed to mid-Feb
Ivory Coast's government said it will receive a first batch of around 100,000 doses of the Pfizer BioNTech coronavirus vaccine in mid February, around two weeks later than initially planned, due to delays in availability of the shots. Government spokesman Sidi Tiemoko Toure said on Wednesday the country plans to roll out its inoculation programme in the first quarter and would authorise vaccines from AstraZeneca , China's Sinopharm and Russia this week. While richer nations have secured and launched mass vaccination campaigns, countries in Africa are still scrambling to secure supplies as most grapple with a second wave of infections.
- Reuters
Three COVID-19 vaccines under final review for emergency use - WHO
The World Health Organization (WHO) said on Wednesday that three COVID-19 vaccines were in the late stages of review for possible emergency use listing, in addition to the one made by Pfizer and BioNTech already approved. The WHO was not aware of any deaths linked to the Pfizer vaccine, nor any other vaccine, she added.
